Succinimide Anticonvulsants for Autism Expressive Language Deficit
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is currently no FDA-approved pharmacological treatment for expressive language deficit in autism spectrum disorder (ASD), and existing antiepileptic drugs (AEDs) have not been recognized for their potential role in addressing this specific communication disorder.
Innovation Solution
Administering a therapeutically effective amount of succinimide anticonvulsants, such as ethosuximide, methsuximide, or phensuximide, to autistic individuals over an extended period, typically at least one month, to improve their expressive language and conversational abilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If succinimide anticonvulsants are administered to autistic individuals, then expressive language skills are significantly enhanced, but no FDA-approved pharmacological treatment currently exists for this specific condition
Solution Approach 1:
The patent applies parameter changes by administering succinimide anticonvulsants (such as ethosuximide, methsuximide, or phensuximide) at therapeutically effective doses over an extended period (typically at least one month). This pharmacological intervention changes the neurochemical parameters in the brain, thereby enhancing expressive language skills in autistic individuals. The treatment transforms the patient's language capability from single words to full sentences or spontaneous speech through sustained medication administration.
2Reliability
If existing antiepileptic drugs are used for their approved indications, then seizure control is achieved, but their potential role in addressing expressive language deficit in ASD is not recognized
Solution Approach 1:
The patent applies universality by demonstrating that succinimide anticonvulsants, already approved for seizure control, also possess the ability to treat expressive language deficits in autism spectrum disorder. The same drug class (ethosuximide, methsuximide, phensuximide) serves multiple functions: controlling seizures and enhancing expressive language skills. This multi-functionality allows the treatment to address both neurological and communicative needs of autistic patients using a single pharmacological agent.
3Duration of action of stationary object
If treatment is administered for an extended period of at least one month, then language improvements are sustained even after discontinuation, but the treatment requires long-term commitment
Solution Approach 1:
The patent applies preliminary action by requiring treatment to be administered for an extended period (at least one month, typically longer) before discontinuation. This sustained preliminary treatment establishes lasting neurological changes that enable language improvements to be maintained even after the medication is stopped. The long-term commitment ensures that the therapeutic effect is fully established and becomes sustained in the patient's system.
Data Source
AI summary
A pharmacological method for treating the expressive language deficit in an autistic human child or adult is provided. A therapeutically effective dose of a succinimide anticonvulsant, e.g., ethosuximide, methsuximide, phensuximide, or a pharmaceutically acceptable salt thereof, is administered to a patient suffering from expressive language deficit, preferably over an extended period, e.g., six months or longer. Language gains are retained even after treatment is discontinued.